Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Deal History & Licensing Activity
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is a life sciences. Over the past three years, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) has been involved in 9 licensing and acquisition transactions, with a primary focus on ADC (7 deals).
Deals (12mo)
4
Active Trials
0
Top Modality
ADC
Focus Area
Women's Health
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| muscle disorder capsid | Astellas | Gene Therapy | Unknown | license | Apr 2026 |
| muscle disorder capsid | Astellas | Gene Therapy | Unknown | license | Apr 2026 |
| CLDN18.2-targeting ADC | Astellas | ADC | Unknown | license |
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Pipeline Focus
Therapeutic areas and modalities where Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Strategic Signals
Key indicators of Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Women's Health assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) Licensing & Deal Activity
Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 9 deals over the past three years, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) include Women's Health (5 deals and trials), Mega Deals (4 deals and trials), and Codev Deals (3 deals and trials). In terms of modality, Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) has shown particular interest in adc, gene therapy, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.